Education
About Us
Working with TipRanks
Follow Us
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD)
ASX:RMD
RESEARCH TOOLSreports
Earnings Data
Report Date
Jul 31, 2025After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.38Last Year’s EPS
0.21Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance, gross margin expansion, new product launches, significant investments in manufacturing and R&D, and recognition for innovation. However, challenges such as sleep lab backlogs and negative currency impacts were noted. Overall, the highlights significantly outweigh the lowlights, indicating a positive outlook.Company Guidance -
Q3 2025
Strong Financial Performance in Q3
Group revenue for the March quarter was $1.29 billion, an 8% headline increase and 9% in constant currency terms. Operating profit for the quarter increased by 13% underpinned by revenue growth and gross margin expansion.
Gross Margin Expansion
Gross margin increased by 140 basis points to 59.9% in the March quarter. The increase was driven by manufacturing and logistics efficiencies, favorable shifts in product mix, and component cost improvements.
New Product Launches
The first full commercial rollout of Nite Owl and the launch of AirSense eleven version of ZPAP Tx in the US market. These products are expected to enhance diagnostic capabilities and patient care.
Investment in Manufacturing and R&D
ResMed is opening a new manufacturing facility in Calabasas, California, which will double US manufacturing capacity. The company continues to invest 6-7% of its revenue into research and development.
Recognition for Innovation
ResMed was named in the Lexus Nexus list of the top one hundred global innovators for its market-leading efforts in driving pioneering innovation.
Significant Cash Flow and Share Buyback Program
Cash flow from operations for the quarter was $579 million, and the company plans to increase its ongoing share buyback program to $100 million per quarter.
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) Earnings, Revenues Date & History
AU:RMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AU:RMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 23, 2025 | AU$33.18 | AU$36.00 | +8.50% |
Jan 30, 2025 | AU$40.32 | AU$40.00 | -0.79% |
Oct 24, 2024 | AU$35.39 | AU$37.48 | +5.91% |
Aug 01, 2024 | AU$32.10 | AU$31.52 | -1.81% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) report earnings?
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) is schdueled to report earning on Jul 31, 2025, After Close (Confirmed).
What is Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) earnings time?
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) earnings time is at Jul 31, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock?
The P/E ratio of Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh is N/A.
What is AU:RMD EPS forecast?
AU:RMD EPS forecast for the fiscal quarter 2025 (Q4) is 0.38.